Medincell SA (PA:MEDCL) — Market Cap & Net Worth
Market Cap & Net Worth: Medincell SA (MEDCL)
Medincell SA (PA:MEDCL) has a market capitalization of $790.73 Million (€676.36 Million) as of September 17, 2026. Listed on the PA stock exchange, this France-based company holds position #9958 globally and #155 in its home market, demonstrating a -6.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medincell SA's stock price €21.40 by its total outstanding shares 35909836 (35.91 Million). Also see Medincell SA assets under control for a full breakdown of the balance sheet.
Medincell SA Market Cap History: 2018 to 2026
Medincell SA's market capitalization history from 2018 to 2026. Data shows growth from $279.18 Million to $898.42 Million (14.40% CAGR). Also see Medincell SA (MEDCL) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Medincell SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$230.53 Billion | 0.34% | #56 of 119 |
|
CAC Small90
CACS
|
$36.86 Billion | 2.15% | #13 of 64 |
|
CAC All-Tradable
CACT
|
$2.85 Trillion | 0.03% | #115 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.85 Trillion | 0.03% | #115 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.85 Trillion | 0.03% | #115 of 179 |
|
CAC Health Care
FRHC
|
$241.84 Billion | 0.33% | #13 of 36 |
Weight: Medincell SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Medincell SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medincell SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MEDCL live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
46.02x
Medincell SA's market cap is 46.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $279.18 Million | $6.44 Million | -$9.57 Million | 43.36x | N/A |
| 2019 | $288.84 Million | $1.44 Million | -$19.69 Million | 200.17x | N/A |
| 2020 | $428.22 Million | $2.85 Million | -$23.91 Million | 150.15x | N/A |
| 2021 | $419.82 Million | $8.19 Million | -$19.02 Million | 51.29x | N/A |
| 2022 | $259.45 Million | $4.09 Million | -$24.81 Million | 63.44x | N/A |
| 2023 | $302.27 Million | $9.94 Million | -$32.01 Million | 30.40x | N/A |
| 2024 | $697.75 Million | $9.16 Million | -$25.04 Million | 76.17x | N/A |
| 2025 | $1.06 Billion | $25.54 Million | -$18.44 Million | 41.42x | N/A |
| 2026 | $898.42 Million | $19.52 Million | -$31.29 Million | 46.02x | N/A |
Competitor Companies of MEDCL by Market Capitalization
Companies near Medincell SA in the global market cap rankings as of September 17, 2026. Review MEDCL goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Medincell SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Medincell SA Historical Marketcap From 2018 to 2026
Between 2018 and today, Medincell SA's market cap moved from $279.18 Million to $ 898.42 Million, with a yearly change of 14.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €898.42 Million | -15.08% |
| 2025 | €1.06 Billion | +51.62% |
| 2024 | €697.75 Million | +130.83% |
| 2023 | €302.27 Million | +16.50% |
| 2022 | €259.45 Million | -38.20% |
| 2021 | €419.82 Million | -1.96% |
| 2020 | €428.22 Million | +48.26% |
| 2019 | €288.84 Million | +3.46% |
| 2018 | €279.18 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Medincell SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $790.73 Million USD |
| MoneyControl | $790.73 Million USD |
| MarketWatch | $790.73 Million USD |
| marketcap.company | $790.73 Million USD |
| Reuters | $790.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medincell SA
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment … Read more